Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma – a Phase II Study
Carl Shultz(West Virginia University), Lauren Veltri(West Virginia University), Mehdi Hamadani(Medical College of Wisconsin), Chelby Wakefield(West Virginia University), Sijin Wen(The University of Texas MD Anderson Cancer Center), Abraham S. Kanate(HonorHealth), Michael Craig(Edith Cowan University), Aaron Cumpston(West Virginia University Hospitals), Kelly Ross(West Virginia University), Steven Rollins(West Virginia University)
Cited by 0
Related Papers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441